TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07312903: DPTX3186 in Wnt Pathway Activated Solid Tumors

Sponsor: Dewpoint Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07312903 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07312903 Rescue Dossier →